tiprankstipranks
Vertex Pharmaceuticals (IT:1VRTX)
:1VRTX
Italy Market
1VRTX
Vertex Pharmaceuticals
RESEARCH TOOLSreports

Vertex Pharmaceuticals (1VRTX) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

1VRTX Analyst Ratings

Strong Buy
28Ratings
Strong Buy
22 Buy
5 Hold
1 Sell
Based on 28 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1VRTX Stock 12 Month Forecast

Average Price Target

€488.07
▲(14.75% Upside)
Based on 28 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is €488.07 with a high forecast of €566.32 and a low forecast of €304.01. The average price target represents a 14.75% change from the last price of €425.35.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"303":"€303","369":"€369","435":"€435","501":"€501","567":"€567"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":566.32027576,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€566.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":488.07170204869556,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€488.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":304.006283,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€304.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[303,369,435,501,567],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,411.2,423.13232890461535,435.06465780923077,446.9969867138461,458.9293156184615,470.8616445230769,482.79397342769226,494.7263023323077,506.65863123692304,518.5909601415384,530.5232890461538,542.4556179507692,554.3879468553846,{"y":566.32027576,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,411.2,417.11320784989965,423.0264156997993,428.939623549699,434.85283139959864,440.7660392494983,446.6792470993979,452.5924549492976,458.50566279919724,464.4188706490969,470.33207849899657,476.24528634889623,482.1584941987959,{"y":488.07170204869556,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,411.2,402.95432946153846,394.70865892307694,386.46298838461536,378.21731784615383,369.9716473076923,361.7259767692308,353.4803062307692,345.2346356923077,336.98896515384615,328.7432946153846,320.4976240769231,312.2519535384615,{"y":304.006283,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":397.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":388.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":398.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":415.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":388.65,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":365.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":373,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":438,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":411.2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€566.32Average Price Target€488.07Lowest Price Target€304.01
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on IT:1VRTX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/04/26
Analysts' Top Healthcare Picks: Danaher (DHR), Vertex Pharmaceuticals (VRTX)
Evercore ISI Analyst forecast on IT:1VRTX
Cory Kasimov
Evercore ISI
Evercore ISI
€464.7
Buy
9.25%
Upside
Reiterated
08/04/26
Evercore ISI Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
H.C. Wainwright Analyst forecast on IT:1VRTX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€556.77
Buy
30.90%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK)
Needham Analyst forecast on IT:1VRTX
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
08/04/26
Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold
Stifel Nicolaus Analyst forecast on IT:1VRTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€404.76→€434.29
Hold
2.10%
Upside
Reiterated
08/04/26
Stifel Nicolaus Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on IT:1VRTX
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€378.7→€383.92
Hold
-9.74%
Downside
Reiterated
08/04/26
Vertex: Solid CF Fundamentals and Early Pipeline Credit Drive Price Target Raise to $442, Hold Rating Maintained
Truist Financial Analyst forecast on IT:1VRTX
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (NYSE: AMN), Fresenius Medical Care (NYSE: FMS) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Wells Fargo Analyst forecast on IT:1VRTX
Mohit Bansal
Wells Fargo
Wells Fargo
€469.04→€477.72
Buy
12.31%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo
TD Cowen Analyst forecast on IT:1VRTX
Phil Nadeau
TD Cowen
TD Cowen
€456.01→€477.72
Buy
12.31%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Receives a Buy from TD Cowen
Cantor Fitzgerald Analyst forecast on IT:1VRTX
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€512.47→€516.81
Buy
21.50%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Stoke Therapeutics (NASDAQ: STOK) and SI-Bone (NASDAQ: SIBN)
Scotiabank Analyst forecast on IT:1VRTX
Louise Chen
Scotiabank
Scotiabank
€484.67
Buy
13.95%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Scotiabank
UBS Analyst forecast on IT:1VRTX
Michael Yee
UBS
UBS
€508.12
Buy
19.46%
Upside
Reiterated
08/04/26
Vertex: Buy Rating Reaffirmed with Unchanged $585 Price Target on Strong CF Performance and Late-Stage Pipeline Upside
Wolfe Research Analyst forecast on IT:1VRTX
Andy Chen
Wolfe Research
Wolfe Research
€483.8
Buy
13.74%
Upside
Reiterated
08/03/26
Vertex: Strong Q2 Beat and Raised Revenue Outlook Underpin Buy Rating and Broadening Growth Beyond CF
Bank of America Securities Analyst forecast on IT:1VRTX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€521.15→€525.5
Buy
23.54%
Upside
Reiterated
08/03/26
Vertex Upgraded to Buy as Strong Q2, Raised 2026 Guidance and Higher $605 Price Target Signal Durable, Diversified Growth
Goldman Sachs Analyst forecast on IT:1VRTX
Salveen Richter
Goldman Sachs
Goldman Sachs
€566.32
Buy
33.14%
Upside
Reiterated
07/27/26
Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (NASDAQ: BMRN), Zoetis (NYSE: ZTS) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on IT:1VRTX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/04/26
Analysts' Top Healthcare Picks: Danaher (DHR), Vertex Pharmaceuticals (VRTX)
Evercore ISI Analyst forecast on IT:1VRTX
Cory Kasimov
Evercore ISI
Evercore ISI
€464.7
Buy
9.25%
Upside
Reiterated
08/04/26
Evercore ISI Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
H.C. Wainwright Analyst forecast on IT:1VRTX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€556.77
Buy
30.90%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK)
Needham Analyst forecast on IT:1VRTX
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
08/04/26
Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold
Stifel Nicolaus Analyst forecast on IT:1VRTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€404.76→€434.29
Hold
2.10%
Upside
Reiterated
08/04/26
Stifel Nicolaus Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on IT:1VRTX
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€378.7→€383.92
Hold
-9.74%
Downside
Reiterated
08/04/26
Vertex: Solid CF Fundamentals and Early Pipeline Credit Drive Price Target Raise to $442, Hold Rating Maintained
Truist Financial Analyst forecast on IT:1VRTX
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (NYSE: AMN), Fresenius Medical Care (NYSE: FMS) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Wells Fargo Analyst forecast on IT:1VRTX
Mohit Bansal
Wells Fargo
Wells Fargo
€469.04→€477.72
Buy
12.31%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo
TD Cowen Analyst forecast on IT:1VRTX
Phil Nadeau
TD Cowen
TD Cowen
€456.01→€477.72
Buy
12.31%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Receives a Buy from TD Cowen
Cantor Fitzgerald Analyst forecast on IT:1VRTX
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€512.47→€516.81
Buy
21.50%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Stoke Therapeutics (NASDAQ: STOK) and SI-Bone (NASDAQ: SIBN)
Scotiabank Analyst forecast on IT:1VRTX
Louise Chen
Scotiabank
Scotiabank
€484.67
Buy
13.95%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Scotiabank
UBS Analyst forecast on IT:1VRTX
Michael Yee
UBS
UBS
€508.12
Buy
19.46%
Upside
Reiterated
08/04/26
Vertex: Buy Rating Reaffirmed with Unchanged $585 Price Target on Strong CF Performance and Late-Stage Pipeline Upside
Wolfe Research Analyst forecast on IT:1VRTX
Andy Chen
Wolfe Research
Wolfe Research
€483.8
Buy
13.74%
Upside
Reiterated
08/03/26
Vertex: Strong Q2 Beat and Raised Revenue Outlook Underpin Buy Rating and Broadening Growth Beyond CF
Bank of America Securities Analyst forecast on IT:1VRTX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€521.15→€525.5
Buy
23.54%
Upside
Reiterated
08/03/26
Vertex Upgraded to Buy as Strong Q2, Raised 2026 Guidance and Higher $605 Price Target Signal Durable, Diversified Growth
Goldman Sachs Analyst forecast on IT:1VRTX
Salveen Richter
Goldman Sachs
Goldman Sachs
€566.32
Buy
33.14%
Upside
Reiterated
07/27/26
Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (NASDAQ: BMRN), Zoetis (NYSE: ZTS) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months
Mohit BansalWells Fargo
Success Rate
24/33 ratings generated profit
73%
Average Return
+6.94%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +6.94% per trade.
1 Year
Mohit BansalWells Fargo
Success Rate
24/33 ratings generated profit
73%
Average Return
+13.43%
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +13.43% per trade.
2 Years
Geoff MeachamCiti
Success Rate
35/41 ratings generated profit
85%
Average Return
+16.87%
Copying Geoff Meacham's trades and holding each position for 2 Years would result in 85.37% of your transactions generating a profit, with an average return of +16.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1VRTX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
45
42
33
50
45
Hold
13
11
9
9
8
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
58
53
42
60
54
In the current month, 1VRTX has received 45 Buy Ratings, 8 Hold Ratings, and 1 Sell Ratings. 1VRTX average Analyst price target in the past 3 months is 488.07.
Each month's total comprises the sum of three months' worth of ratings.

1VRTX Financial Forecast

1VRTX Earnings Forecast

Next quarter’s earnings estimate for 1VRTX is €4.16 with a range of €3.20 to €4.51. The previous quarter’s EPS was €4.11. 1VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.89% of the time in the same period. In the last calendar year 1VRTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1VRTX is €4.16 with a range of €3.20 to €4.51. The previous quarter’s EPS was €4.11. 1VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.89% of the time in the same period. In the last calendar year 1VRTX has Performed in-line its overall industry.

1VRTX Sales Forecast

Next quarter’s sales forecast for 1VRTX is €2.95B with a range of €2.88B to €3.04B. The previous quarter’s sales results were €2.90B. 1VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.47% of the time in the same period. In the last calendar year 1VRTX has Performed in-line its overall industry.
Next quarter’s sales forecast for 1VRTX is €2.95B with a range of €2.88B to €3.04B. The previous quarter’s sales results were €2.90B. 1VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.47% of the time in the same period. In the last calendar year 1VRTX has Performed in-line its overall industry.

1VRTX Stock Forecast FAQ

What is IT:1VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 488.07.
    What is IT:1VRTX’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals has 14.75% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Vertex Pharmaceuticals a Buy, Sell or Hold?
          Vertex Pharmaceuticals has a consensus rating of Strong Buy, which is based on 22 buy ratings, 5 hold ratings and 1 sell ratings.
            What is Vertex Pharmaceuticals’s share price target?
            The average share price target for Vertex Pharmaceuticals is 488.07. This is based on 28 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €566.32 ,and the lowest forecast is €304.01. The average share price target represents 14.75% Increase from the current price of €425.35.
              What do analysts say about Vertex Pharmaceuticals?
              Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 28 Wall Streets Analysts.
                How can I buy shares of Vertex Pharmaceuticals?
                To buy shares of IT:1VRTX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.